Mayo Clinic

Their core work

Mayo Clinic is one of the world's foremost not-for-profit academic medical centers, combining clinical care with translational research at scale. In its H2020 participation, it contributed specialist expertise in clinical genetics, cancer risk stratification, and immunological disease mechanisms — the kind of real-world patient cohort access and diagnostic validation capacity that European academic consortia rarely have internally. Its role is to bridge laboratory findings with clinical practice: translating genetic sequencing data into actionable risk predictions for patients, and mapping immunological pathways that drive chronic disease relapse. Working as a sought-after participant rather than a lead, Mayo brings validated clinical knowledge and large-scale patient data to research consortia.

What they specialise in

How they've shifted over time

Both H2020 projects launched simultaneously in 2015, which means the keyword split between "early" and "recent" reflects two parallel research streams rather than a true temporal shift — BRIDGES ran until 2021 and covered cancer genetics, while RELENT ran until 2020 and covered autoimmune disease. Viewed together, Mayo's H2020 profile reveals a dual specialisation: precision medicine for cancer risk on one side, and immune-mediated chronic disease on the other. The common thread is predictive and preventive medicine — moving from disease diagnosis toward earlier intervention and risk stratification.

Mayo's H2020 footprint points toward a dual competence in genomic risk prediction and immune-mediated disease, making them a strong candidate for future consortia in precision oncology, personalised immunotherapy, or aging-related chronic disease prevention.

How they like to work

Mayo Clinic participates exclusively as a consortium member in H2020 — never as coordinator — which is typical for major US institutions joining European projects: they contribute specialist clinical capacity rather than project management. With 30 unique partners across 11 countries reached through just 2 projects, they operate within large, diverse international consortia rather than small bilateral arrangements. This suggests they are brought in for a specific, high-value function — most likely patient cohort access, clinical validation, or expert medical review — rather than as generalist research partners.

Mayo has worked with 30 distinct consortium partners spread across 11 countries through only 2 projects, indicating involvement in large, geographically diverse consortia. As a US-based institution in H2020, its network is inherently transatlantic and likely anchored by European academic medical centres leading the projects.

What sets them apart

Mayo Clinic brings something most European research organisations simply cannot replicate: one of the world's largest integrated clinical research infrastructures, with access to deep patient registries, decades of longitudinal health data, and cross-disciplinary clinical teams under one roof. For a European consortium seeking clinical validation of a genetic test, a diagnostic tool, or an immunological biomarker, having Mayo as a partner adds immediate credibility and real-world testing capacity that accelerates the path from research to clinical adoption. Their non-profit research mission also aligns well with publicly funded EU projects in ways that for-profit hospital networks often do not.

Highlights from their portfolio

• BRIDGES
  A long-running (2015–2021) multi-national effort to build population-level breast cancer risk models from gene sequencing data — one of the most ambitious cancer genetics consortia in H2020, where Mayo's clinical cohort access would have been central.
• RELENT
  Tackled the underexplored problem of relapse prevention across multiple chronic autoimmune diseases simultaneously, seeking shared immunological mechanisms — a cross-disease approach that demands the kind of large, diverse patient populations Mayo routinely manages.